Health Care • Biotechnology: Pharmaceutical Preparations
$11.06 ▼ -0.02
(-0.18%)
MKT CAP: $692.2M • VOL: 276.6K
52W L $6 52W H $17
DSGN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$79.5M | -$62.4M | -$78.2M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$69.8M | -$49.6M | -$66.9M |
| EBITDA (Normalized) | -$79.3M | -$62.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$54.4M | -$43.1M | -$58.6M |
| Capital Expenditures (CapEx) | $193.0K | $340.0K | — |
| Free Cash Flow (FCF) | -$54.6M | -$43.4M | -$58.6M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -32.1% | -22.4% | — |
| Cash & Short-Term Equivalents | $16.9M | $22.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $212.5M | $242.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DSGN.